Kershaw Victoria, Jha Swati
James Cook University Hospital, Middlesbrough, TS4 3BW, UK.
Jessop Wing, Tree Root Walk, Sheffield, S10 2SF, UK.
Int J Womens Health. 2024 Nov 14;16:1909-1938. doi: 10.2147/IJWH.S446903. eCollection 2024.
Genitourinary syndrome of the menopause (GSM) is a chronic, often progressive condition, characterised by symptoms relating to oestrogen deficiency including; vaginal dryness, burning, itching, dyspareunia, dysuria, urinary urgency and recurrent urinary tract infections. GSM affects up to 70% of breast cancer survivors with a tendency to particularly severe symptoms, owing to the effects of iatrogenic menopause and endocrine therapy. Patients and clinicians can be reluctant to replace oestrogen vaginally due to fear of cancer recurrence. Vaginal laser is a novel therapy, which may become a valuable nonhormonal alternative in GSM treatment. There are currently 6 published studies regarding Erbium:YAG laser treatment for GSM, 41 studies regarding CO2 laser treatment for GSM and 28 studies regarding vaginal laser treatment for GSM in breast cancer survivors. Number of participants ranges from 12 to 645. The majority of studies describe a course of 3 treatments, but some report outcomes after 5. Significant improvements were reported in vaginal dryness, burning, dyspareunia, itch, Vaginal Health Index Scores (VHIS), Quality of Life, and FSFI (Female Sexual Function Index). Most studies reported outcomes at short-term follow-up from 30 days to 12 months post-treatment. Few studies report longer-term outcomes with conflicting results. Whilst some studies suggest improvements are sustained up to 24 months, others report a drop-off in symptom improvement at 12-18 months. Patient satisfaction ranged from 52% to 90% and deteriorated with increasing time post-procedure in one study. The findings in this review must be validated in robust randomised sham-controlled trials of adequate power. There remain a number of unanswered questions in terms of which laser medium to use, optimal device settings, ideal interval between treatments, pre-treatment vaginal preparation, as well as safety and efficacy of repeated treatments long term. These issues could be addressed most efficiently with a mandatory registry of vaginal laser procedures.
更年期泌尿生殖综合征(GSM)是一种慢性且通常呈进行性发展的病症,其特征为与雌激素缺乏相关的症状,包括阴道干燥、烧灼感、瘙痒、性交困难、排尿困难、尿急以及复发性尿路感染。由于医源性绝经和内分泌治疗的影响,高达70%的乳腺癌幸存者会受到GSM影响,且症状往往较为严重。患者和临床医生因担心癌症复发而不愿经阴道补充雌激素。阴道激光是一种新型疗法,可能成为GSM治疗中有价值的非激素替代方法。目前有6项关于铒激光治疗GSM的已发表研究、41项关于二氧化碳激光治疗GSM的研究以及28项关于乳腺癌幸存者阴道激光治疗GSM的研究。参与者人数从12人到645人不等。大多数研究描述的是3次治疗疗程,但也有一些报告了5次治疗后的结果。据报告,阴道干燥、烧灼感、性交困难、瘙痒、阴道健康指数评分(VHIS)、生活质量和女性性功能指数(FSFI)均有显著改善。大多数研究报告了治疗后30天至12个月短期随访的结果。很少有研究报告长期结果,且结果相互矛盾。虽然一些研究表明改善可持续长达24个月,但另一些研究报告称在12至18个月时症状改善有所下降。一项研究中患者满意度在52%至90%之间,且随着术后时间的增加而恶化。本综述中的研究结果必须在足够样本量的严格随机假对照试验中得到验证。在使用哪种激光介质、最佳设备设置、治疗间隔理想时长、治疗前阴道准备以及长期重复治疗的安全性和有效性等方面,仍有许多问题未得到解答。通过强制性的阴道激光手术登记可以最有效地解决这些问题。